Sector News

Taisho said to near $1.6 billion deal for Bristol-Myers’s UPSA: Bloomberg

December 26, 2018
Life sciences

Japanese healthcare firm Taisho Pharmaceutical Holdings Co Ltd is said to be close to a $1.6 billion deal for Bristol-Myers Squibb Co’s French over-the-counter drugs business UPSA, Bloomberg reported on Sunday, citing sources familiar with the matter.

An agreement for the consumer-health business could be announced as soon as this week, according to the report bloom.bg/2QyHulF.

Bristol-Myers Squibb said in an email to Reuters that it does not comment on rumors and speculation, adding that the company is still considering options for the strategic review of UPSA that was announced in June.

A Taisho spokesman said the company could not comment on the report.

German drugmaker Stada and Italian healthcare company Angelini were among the final bidders for Bristol-Myers’ UPSA unit, according to a Reuters report in November.

By Bhanu Pratap

Source: Reuters

comments closed

Related News

February 17, 2024

GSK concludes Aiolos Bio acquisition for $1.4bn

Life sciences

The agreement, signed last month, includes an upfront payment of $1bn and $400m in regulatory milestone payments. The acquisition introduces AIO-001, a long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody, into GSK’s pipeline.

February 17, 2024

CRISPR gene therapy Casgevy secures approval in Europe

Life sciences

Vertex Pharmaceuticals and CRISPR Therapeutics have scored another regulatory approval for Casgevy (exagamglogene autotemcel) after the European Commission granted conditional marketing authorisation to the gene therapy.

February 17, 2024

Gilead to buy liver drugmaker CymaBay for $4.3 Billion

Life sciences

US biopharmaceutical company Gilead Sciences is to acquire CymaBay Therapeutics for $4.3 billion. Gilead offered to purchase all outstanding shares of CymaBay for $32.50 per share in cash. CymaBay, based in the US near San Francisco, California, has developed the investigational drug seladelpar, which is currently in clinical Phase 3.

How can we help you?

We're easy to reach